[HTML][HTML] Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19

J Hammond, H Leister-Tebbe, A Gardner… - … England Journal of …, 2022 - Mass Medical Soc
Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

[HTML][HTML] REGEN-COV antibody combination and outcomes in outpatients with Covid-19

DM Weinreich, S Sivapalasingam… - … England Journal of …, 2021 - Mass Medical Soc
Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study

F Buttgereit, V Strand, EB Lee, A Simon-Campos… - RMD open, 2019 - rmdopen.bmj.com
Objectives Glucocorticoids have anti-inflammatory, transrepression-mediated effects,
although adverse events (AEs; transactivation-mediated effects) limit long-term use in …

A phase 2 trial of peresolimab for adults with rheumatoid arthritis

J Tuttle, E Drescher, JA Simón-Campos… - … England Journal of …, 2023 - Mass Medical Soc
Background Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate
the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of …

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …

H Montgomery, FDR Hobbs, F Padilla… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …

[HTML][HTML] Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in …

SA Halperin, L Ye, D MacKinnon-Cameron, B Smith… - The Lancet, 2022 - thelancet.com
Summary Background The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5)
vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and …

Favipiravir in patients with early mild-to-moderate coronavirus disease 2019 (COVID-19): a randomized controlled trial

Y Golan, JAS Campos, R Woolson… - Clinical Infectious …, 2023 - academic.oup.com
Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …

REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients

DM Weinreich, S Sivapalasingam, T Norton, S Ali… - MedRxiv, 2021 - medrxiv.org
Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)

A Horga, R Saenz, G Yilmaz, A Simón-Campos… - Future …, 2023 - Future Medicine
Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of
bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods …

Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial

MC Genovese, C Pacheco-Tena… - The Journal of …, 2018 - jrheum.org
Objective. To assess 5-year safety, tolerability, and efficacy of subcutaneous (SC) abatacept
(ABA) in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods. The …